Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.

Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho BC, Turna HZ, Castro G Jr, Srimuninnimit V, Laktionov KK, Bondarenko I, Kubota K, Lubiniecki GM, Zhang J, Kush D, Lopes G; KEYNOTE-042 Investigators.

Lancet. 2019 May 4;393(10183):1819-1830. doi: 10.1016/S0140-6736(18)32409-7. Epub 2019 Apr 4.

PMID:
30955977
2.

Diagnostic Yield of Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration Cytological Smears and Cell Blocks: A Single-Institution Experience.

Žemaitis M, Musteikienė G, Miliauskas S, Pranys D, Sakalauskas R.

Medicina (Kaunas). 2018 Apr 18;54(2). pii: E19. doi: 10.3390/medicina54020019.

3.

Factors associated with sputum culture conversion in patients with pulmonary tuberculosis.

Musteikienė G, Miliauskas S, Zaveckienė J, Žemaitis M, Vitkauskienė A.

Medicina (Kaunas). 2017;53(6):386-393. doi: 10.1016/j.medici.2018.01.005. Epub 2018 Feb 9.

4.

Distribution of M1 and M2 macrophages in tumor islets and stroma in relation to prognosis of non-small cell lung cancer.

Jackute J, Zemaitis M, Pranys D, Sitkauskiene B, Miliauskas S, Vaitkiene S, Sakalauskas R.

BMC Immunol. 2018 Jan 24;19(1):3. doi: 10.1186/s12865-018-0241-4.

5.

Cisplatin-induced sudden cardiac death with hemodynamic collapse: a severe adverse drug reaction: Case report.

Abramavicius S, Zemaitis M, Pilvinis V, Kadusevicius E.

Medicine (Baltimore). 2017 Dec;96(48):e8995. doi: 10.1097/MD.0000000000008995.

6.

Multidrug-resistant tuberculosis in Lithuania - Still a long way ahead.

Musteikienė G, Miliauskas S, Sakalauskas R, Vitkauskienė A, Žemaitis M.

Medicina (Kaunas). 2016;52(2):69-78. doi: 10.1016/j.medici.2016.02.002. Epub 2016 Mar 3. Review.

7.

Distribution of CD4(+) and CD8(+) T cells in tumor islets and stroma from patients with non-small cell lung cancer in association with COPD and smoking.

Jackutė J, Žemaitis M, Pranys D, Šitkauskienė B, Miliauskas S, Bajoriūnas V, Sakalauskas R.

Medicina (Kaunas). 2015 Nov;51(5):263-71. doi: 10.1016/j.medici.2015.08.002. Epub 2015 Sep 21.

8.

The prognostic influence of tumor infiltrating Foxp3(+)CD4(+), CD4(+) and CD8(+) T cells in resected non-small cell lung cancer.

Jackute J, Zemaitis M, Pranys D, Sitkauskiene B, Miliauskas S, Bajoriunas V, Lavinskiene S, Sakalauskas R.

J Inflamm (Lond). 2015 Nov 23;12:63. doi: 10.1186/s12950-015-0108-x. eCollection 2015.

9.

Local and systemic neutrophilic inflammation in patients with lung cancer and chronic obstructive pulmonary disease.

Vaguliene N, Zemaitis M, Lavinskiene S, Miliauskas S, Sakalauskas R.

BMC Immunol. 2013 Aug 6;14:36. doi: 10.1186/1471-2172-14-36.

10.

The role of mutation status of the epidermal growth factor receptor gene in advanced non-small cell lung cancer.

Vagulienė N, Žemaitis M, Šarauskas V, Vitkauskienė A, Miliauskas S.

Medicina (Kaunas). 2012;48(4):175-81.

11.

Pseudoaneurysm of brachiocephalic artery mimicking the mediastinal tumor.

Miliauskas S, Benetis R, Zemaitis M, Zaveckiene J, Sakalauskas R.

Respir Med Case Rep. 2012 Sep 7;6:7-10. doi: 10.1016/j.rmcr.2012.08.001. eCollection 2012.

12.

Comparison of C-reactive protein levels in patients with lung cancer and chronic obstructive pulmonary disease.

Vagulienė N, Žemaitis M, Miliauskas S, Urbonienė D, Šitkauskienė B, Sakalauskas R.

Medicina (Kaunas). 2011;47(8):421-7. Epub 2011 Nov 18.

13.

Sarcoidosis--moving to the new standard of diagnosis?

Miliauskas S, Zemaitis M, Sakalauskas R.

Medicina (Kaunas). 2010;46(7):443-6. Review.

14.

Late-onset nocturnal intractable seizure during sleep: what is the origin?

Miliauskas S, Liesiene V, Zemaitis M, Sakalauskas R.

Medicina (Kaunas). 2010;46(2):120-4.

15.

Malignant pleural and peritoneal mesothelioma: incidental diagnosis and excellent treatment results.

Miliauskas S, Zemaitis M, Pranys D.

J Thorac Oncol. 2009 Mar;4(3):435-6. doi: 10.1097/JTO.0b013e3181989551. No abstract available.

16.

Prognostic significance of RASSF1A promoter methylation on survival of non-small cell lung cancer patients treated with gemcitabine.

Fischer JR, Ohnmacht U, Rieger N, Zemaitis M, Stoffregen C, Manegold C, Lahm H.

Lung Cancer. 2007 Apr;56(1):115-23. Epub 2006 Dec 29.

PMID:
17196704
17.

Promoter methylation of RASSF1A, RARbeta and DAPK predict poor prognosis of patients with malignant mesothelioma.

Fischer JR, Ohnmacht U, Rieger N, Zemaitis M, Stoffregen C, Kostrzewa M, Buchholz E, Manegold C, Lahm H.

Lung Cancer. 2006 Oct;54(1):109-16. Epub 2006 Aug 7.

PMID:
16893590
18.

[Clinical and prognostic significance of tumor markers cytokeratin 19 fragment, carcinoembryonic antigen, and neuron-specific enolase in lung cancer].

Zemaitis M, Sakalauskas R, Malakauskas K, Muley T, Fischer JR, Lahm H.

Medicina (Kaunas). 2005;41(7):566-76. Lithuanian.

19.

[Aberrant promoter methylation of tumor suppressor genes in serum from lung cancer patients: frequency and correlation with clinicopathological characteristics].

Zemaitis M, Rieger N, Fischer JR, Sakalauskas R, Malakauskas K, Lahm H.

Medicina (Kaunas). 2005;41(2):123-31. Lithuanian.

Supplemental Content

Loading ...
Support Center